Soft Tissue Sarcoma Market Set for Significant Growth at a CAGR of 7.9% During the Forecast Period (2026-2036), Driven by Novel Therapies and Expanding Treatment Landscape | DelveInsight
The soft tissue sarcoma market across the 7MM is growing driven by increasing disease recognition, improved diagnostic practices, and growing research activity supporting the development of novel therapeutic approaches, including TBI-1301 (mipetresgene autoleucel) (Takara Bio), INT230-6...
The soft tissue sarcoma market across the 7MM is growing driven by increasing disease recognition, improved diagnostic practices, and growing research activity supporting the development of novel therapeutic approaches, including TBI-1301 (mipetresgene autoleucel) (Takara Bio), INT230-6...
Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.